FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2582830599> ?p ?o ?g. }

• W2582830599 endingPage "557" @default.
• W2582830599 startingPage "551" @default.
• W2582830599 abstract "Peptide receptor radionuclide therapy (PRRT), developed over the last two decades, is carried out using radiopharmaceuticals such as 90Y-DOTA-Tyr3-octreotide and 177Lu-DOTA-Tyr3-octreotate (177Lu-Dotatate). These radiocompounds are obtained by labeling a synthetic somatostatin analog with a β-emitting radioisotope. The compounds differ from each other in terms of their energetic features (due to the radionuclide) and peptide receptor affinity (due to the analog) but share the common characteristic of binding specific membrane somatostatin receptors that are (generally) overexpressed in neuroendocrine neoplasms (NENs) and their metastases. NENs are tumors arising from diffuse neuroendocrine system cells that are classified according to grading based on Ki67 percentage values (Grades 1 and 2 are classed as neuroendocrine tumors [NETs]) and to the anatomical site of occurrence (in this paper, we only deal with gastroenteropancreatic [GEP]-NETs, which account for 60%-70% of all NENs). They are also characterized by specific symptoms such as diarrhea and flushing (30% of cases). Despite substantial experience gained in the area of PRRT and its demonstrable effects in terms of efficacy, safety, and improvement in quality of life, these compounds are still not registered (registration of 177Lu-Dotatate for the treatment of midgut NETs is expected soon). Thus, PRRT can only be used in experimental protocols. We provide an overview of the work of leading groups with wide-ranging experience and continuity in data publication in the area of GEP-NET PRRT and report our own personal experience of using different dosage schedules based on the presence of kidney and bone marrow risk factors. Our results on the retreatment of patients previously administered 90Y-DOTA-Tyr3-octreotide with a low dosage of 177Lu-Dotatate are also included. A comment on potential future developments of PRRT in GEP-NETs is provided." @default.
• W2582830599 created "2017-02-03" @default.
• W2582830599 creator A5035448176 @default.
• W2582830599 creator A5043991810 @default.
• W2582830599 creator A5044657023 @default.
• W2582830599 creator A5046802560 @default.
• W2582830599 creator A5057943136 @default.
• W2582830599 creator A5064728742 @default.
• W2582830599 date "2017-01-01" @default.
• W2582830599 modified "2023-09-25" @default.
• W2582830599 title "Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life" @default.
• W2582830599 cites W102016044 @default.
• W2582830599 cites W1707785540 @default.
• W2582830599 cites W1842586218 @default.
• W2582830599 cites W1933764379 @default.
• W2582830599 cites W1967665878 @default.
• W2582830599 cites W1982090431 @default.
• W2582830599 cites W2005674134 @default.
• W2582830599 cites W2005907891 @default.
• W2582830599 cites W2006830353 @default.
• W2582830599 cites W2009629472 @default.
• W2582830599 cites W2017183061 @default.
• W2582830599 cites W2019084269 @default.
• W2582830599 cites W2027676394 @default.
• W2582830599 cites W2028793063 @default.
• W2582830599 cites W2031048655 @default.
• W2582830599 cites W2041147239 @default.
• W2582830599 cites W2052499237 @default.
• W2582830599 cites W2054627587 @default.
• W2582830599 cites W2080318597 @default.
• W2582830599 cites W2090257199 @default.
• W2582830599 cites W2092047830 @default.
• W2582830599 cites W2102617530 @default.
• W2582830599 cites W2120085995 @default.
• W2582830599 cites W2122196655 @default.
• W2582830599 cites W2125398839 @default.
• W2582830599 cites W2154245012 @default.
• W2582830599 cites W2154755646 @default.
• W2582830599 cites W2161816327 @default.
• W2582830599 cites W2182810802 @default.
• W2582830599 cites W2216403306 @default.
• W2582830599 cites W2283093664 @default.
• W2582830599 cites W2337767463 @default.
• W2582830599 cites W2411559315 @default.
• W2582830599 cites W2412941657 @default.
• W2582830599 cites W50698244 @default.
• W2582830599 cites W747418120 @default.
• W2582830599 doi "https://doi.org/10.2147/ott.s97584" @default.
• W2582830599 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5293504" @default.
• W2582830599 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28203088" @default.
• W2582830599 hasPublicationYear "2017" @default.
• W2582830599 type Work @default.
• W2582830599 sameAs 2582830599 @default.
• W2582830599 citedByCount "36" @default.
• W2582830599 countsByYear W25828305992017 @default.
• W2582830599 countsByYear W25828305992018 @default.
• W2582830599 countsByYear W25828305992019 @default.
• W2582830599 countsByYear W25828305992020 @default.
• W2582830599 countsByYear W25828305992021 @default.
• W2582830599 countsByYear W25828305992022 @default.
• W2582830599 countsByYear W25828305992023 @default.
• W2582830599 crossrefType "journal-article" @default.
• W2582830599 hasAuthorship W2582830599A5035448176 @default.
• W2582830599 hasAuthorship W2582830599A5043991810 @default.
• W2582830599 hasAuthorship W2582830599A5044657023 @default.
• W2582830599 hasAuthorship W2582830599A5046802560 @default.
• W2582830599 hasAuthorship W2582830599A5057943136 @default.
• W2582830599 hasAuthorship W2582830599A5064728742 @default.
• W2582830599 hasBestOaLocation W25828305991 @default.
• W2582830599 hasConcept C126322002 @default.
• W2582830599 hasConcept C143998085 @default.
• W2582830599 hasConcept C170493617 @default.
• W2582830599 hasConcept C18903297 @default.
• W2582830599 hasConcept C2776297358 @default.
• W2582830599 hasConcept C2776986829 @default.
• W2582830599 hasConcept C2777286243 @default.
• W2582830599 hasConcept C2779066768 @default.
• W2582830599 hasConcept C2781025020 @default.
• W2582830599 hasConcept C2781283050 @default.
• W2582830599 hasConcept C2989005 @default.
• W2582830599 hasConcept C2993559085 @default.
• W2582830599 hasConcept C3017732841 @default.
• W2582830599 hasConcept C49039625 @default.
• W2582830599 hasConcept C502942594 @default.
• W2582830599 hasConcept C71924100 @default.
• W2582830599 hasConcept C80115893 @default.
• W2582830599 hasConcept C86803240 @default.
• W2582830599 hasConceptScore W2582830599C126322002 @default.
• W2582830599 hasConceptScore W2582830599C143998085 @default.
• W2582830599 hasConceptScore W2582830599C170493617 @default.
• W2582830599 hasConceptScore W2582830599C18903297 @default.
• W2582830599 hasConceptScore W2582830599C2776297358 @default.
• W2582830599 hasConceptScore W2582830599C2776986829 @default.
• W2582830599 hasConceptScore W2582830599C2777286243 @default.
• W2582830599 hasConceptScore W2582830599C2779066768 @default.
• W2582830599 hasConceptScore W2582830599C2781025020 @default.
• W2582830599 hasConceptScore W2582830599C2781283050 @default.
• W2582830599 hasConceptScore W2582830599C2989005 @default.

• next